SignalCorporate
Vertex raises 2026 revenue guidance following mixed Q3 results
Vertex raised 2026 revenue guidance despite mixed Q3 results.
Context
What happened: Vertex Pharmaceuticals (VRTX) slightly raised its 2026 revenue guidance after Q3 results that beat on revenue but missed on non-GAAP EPS.
Key numbers: 2026 revenue guidance $13.15B-$13.25B (consensus $13.28B), up from $13.1B-$13.2B. Q3 non-GAAP EPS $4.76 vs $4.80 a year ago. Revenue $3.44B, up ~12% year over year. Total costs and expenses ~$2.7B, up ~44%.
Why it matters: The guidance increase came alongside a higher expense outlook, and Trikafta/Kaftrio sales declined while newer products posted sharp growth.
Market: -1.0% today ($553.15), +22.3% YTD, 2.1x vol — as of 23:31 UTC
Verified: Q3_2026 (Nov 2) EPS $4.36 vs $4.36 est; next print ~Feb 1
What changed
Vertex Pharmaceuticals (VRTX) slightly raised its 2026 revenue guidance after Q3 results that beat on revenue but missed on non-GAAP EPS.
Why it matters
The guidance increase came alongside a higher expense outlook, and Trikafta/Kaftrio sales declined while newer products posted sharp growth.
Market: -1.0% today ($553.15), +22.3% YTD, 2.1x vol — as of 23:31 UTC
Verified: Q3_2026 (Nov 2) EPS $4.36 vs $4.36 est; next print ~Feb 1